Simulations Plus, Inc. (SLP) Stock Score, Valuation & Financial Research

Simulations Plus, Inc. is in the Technology sector and Software - Application industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 38/100.

Quick answer for SLP

Simulations Plus, Inc. currently has a Wall Street Score of 38/100. The stored market price is $18.42. Its financial score is 35/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.

What Simulations Plus, Inc. does

Simulations Plus, Inc. (SLP) is a worldwide developer of sophisticated software and services aimed at enhancing drug discovery and development processes. The company employs artificial intelligence and machine learning technologies to create tools for modeling, simulation, and predicting molecular characteristics. Its operations are divided into four main business units: Simulations Plus, Cognigen, DILIsym, and Lixoft. Among its diverse software offerings are GastroPlus, which models the absorption and drug interactions of compounds in both human and animal subjects, as well as DDDPlus and MembranePlus for various simulations. The company also provides a range of products built on mechanistic and mathematical models, such as its quantitative systems pharmacology software like DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym. Furthermore, Simulations Plus offers the ADMET Predictor, a chem

SLP financial snapshot

Wall Street Score:
38/100
Current price:
$18.42
Market capitalization:
$372.5M
Revenue:
$82.1M
Net income:
$8.1M
Free cash flow:
$17.4M
Cash:
$35.3M
Total debt:
$487K
EPS:
-3.22
Financial score:
35/100
Valuation score:
0/100
Revenue score:
24/100

What stands out

  • Reported year-over-year revenue growth is +0.0%.
  • Free cash flow is $17.4M, showing positive cash generation.
  • The balance sheet shows $35.3M of cash versus $487K of total debt, leaving more cash than debt.

What the numbers mean

Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.

The financial score is 35/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-07-24.

How to research SLP

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.